FeNO measurement is a validated non-invasive technique, which
is used for diagnosis and monitoring of asthma. It would be
desirable to find a reliable method to monitor allergic rhinitis (AR)
via measurement of FeNO, and/or nasal nitric oxide (nNO). The
aim of our study was the assessment of the efficacy of FeNO and
nNO as markers in AR treatment. FeNO and nNO were measured
with the portable NO analyser (NIOX MINO®) in healthy
participants and in patients with AR. The patients were examined
during the pollen season and out of it. The effect of local
corticosteroids and antihistamine therapy was observed in
patients with AR during pollen season after three weeks of
therapy. There are significant differences between FeNO and
nNO in patients with AR compared to healthy controls at all set
points of measurements. While FeNO responded well to the
treatment with both antihistamines and combined therapy, nNO
decreased only after combined therapy with antihistamines and
nasal corticosteroids. nNO monitoring alone is not a suitable
method to monitor inflammation of the upper airways in AR and
its suppression by anti-allergic treatment and should be
correlated with other markers as FeNO or symptom scores.
Allergic processes are complex disorders in which inflammatory and immunological mechanisms are involved. Many studies indicate that the adhesion molecules are upregulated in allergic inflammation, and play a critical role in the pathogenesis of allergic inflammation. Modulation of the expression of adhesion molecules may provide a potential new target for therapeutic intervention in allergic diseases. In the present study the changes expression of adhesion molecules CDlla, CD18 (LFA-1), CD54 (ICAM-1) and L-selectin (CD62L) and VLA-4 (CD49d) were analysed by flow cytometry. Serum concentrations of soluble ICAM-1, VCAM-1 and soluble low affinity receptor for IgE concentrations sCD23 were measured by ELISA in atopic patients with mild asthma before and after treatment by disodium cromoglycate (DSCG). The most significant finding was a significant decrease of ICAM-1 expression on monocytes and CD49d on monocytes and lymphocytes as well as an increase of L-selectin expression on monocytes after treatment with DSCG, without any associated effect on CDlla and CD18. The levels of soluble ICAM-1 and VCAM-1 were not changed, only the levels of soluble CD23 that plays a regulatory role in ongoing IgE production, were decreased in asthmatic patients after the treatment with DSCG. These results suggest that DSCG diminishes cell activation.